Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treatment of taupathy

一种蛋白病、治疗剂的技术，应用在用于治疗tau蛋白病的组合物和方法领域，能够解决癌细胞无特异性等问题

Inactive Publication Date: 2013-10-09
REVALESIO CORP
View PDF13 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It was developed as a chemotherapeutic agent against cancer, the mechanism of action is to interfere with DNA repair and synthesis, and it has no specificity for cancer cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treatment of taupathy
  • Compositions and methods for treatment of taupathy
  • Compositions and methods for treatment of taupathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0253] microbubble size

[0254] Experiments were carried out with gas-enriched fluids by using the diffuser of the present invention in order to determine the gas bubble size limit. Microbubble size limits were established by passing gas-enriched fluids through 0.22 and 0.1 micron filters. In performing these tests, a volume of fluid was passed through the diffuser of the present invention and a gas-enriched fluid was generated. Sixty milliliters of this fluid was drawn into a 60 ml syringe. The dissolved oxygen level of the fluid in the syringe was then measured by Winkler titration. The fluid in the syringe was injected through a 0.22 micron Millipore Millex GP50 filter into a 50 ml beaker. The dissolved oxygen rate of the material in the 50ml beaker was then measured. The experiment was carried out three times and the results shown in Table 4 below were obtained.

[0255] Table 4

[0256] Dissolved Oxygen in Syringe

Dissolved oxygen after 0.22 micron f...

Embodiment 2

[0260] (cytokine profile determined)

[0261] Pooled lymphocytes were obtained from a healthy voluntary donor. The buffy coat samples were washed to remove platelets according to standard procedures. lymphocytes in 2x10 6 Concentrations per plate were inoculated into RPMI medium (+50 mm HEPES) diluted with gas-enriched fluid of the invention or distilled water (control). Cells were stimulated with 1 μg / ml T3 antigen or 1 μg / ml phytohemagglutinin (PHA) (pan T cell activator) or left unstimulated (recessive control). After 24 hours of incubation, cells were checked for viability and supernatants were extracted and frozen.

[0262] Thaw the supernatant, centrifuge, and use (Luminex) bead lite protocol and platform for testing cytokine expression.

[0263] Two million cells were seeded into 6 wells of a 24-well plate containing complete RPMI + 50 mm Hepes with oxygen-enriched fluid (water) of the invention (wells 1, 3 and 5) or distilled water ( Wells 2, 4 and 6) (dilute 10...

Embodiment 3

[0267] myelin oligodendrocyte glycoprotein (MOG)

[0268] Such as figure 2 As shown, lymphocyte proliferation in response to the MOG antigenic peptide was increased when cultured in the presence of the gas-enriched fluid of the present invention compared to pressurized oxygenated fluid (pressure tank) or deionized control fluid. Thus, the gas-enriched fluids of the present invention can amplify the proliferative response of lymphocytes to antigens of previously primed cells.

[0269] Myelin oligodendrocyte glycoprotein peptide 35-55 (MOG35-55) was synthesized corresponding to the known mouse sequence

[0270] (M-E-V-G-W-Y-R-S-P-F-S-R-O-V-H-L-Y-R-N-G-K) (SEQ ID NO: 1; see patent publication US20080139674, incorporated herein by reference, included for the purpose of this SEQ ID NO: 1). Next, place the 5x10 5 splenocytes were taken from MOG T cell receptor transgenic mice previously immunized with MOG, and reconstituted with the gas-enriched fluid of the present invention,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided are electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegenerative condition or disease (e.g., a taupathy) or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for modulating phosphorylation of tau protein. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membrane potential and / or conductance, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids and therapeutic compositions.

Description

field of invention [0001] Certain aspects relate generally to inflammatory neurodegenerative diseases (e.g., multiple sclerosis (MS), amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, stroke / cerebral ischemia, head Trauma, spinal cord injury, Huntington's disease, migraine, cerebral amyloid angiopathy, inflammatory neurodegenerative disorders associated with AIDS, age-related cognitive decline; tauopathies, mild cognitive impairment, and prions disease) and, in more specific terms, tauopathies (e.g., Alzheimer's disease, argyrophilic grain disease, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobar degeneration (pick Pulverizer's disease) and dementia pugilistica (DP) (also known as chronic boxer's encephalopathy)), and related to the regulation or modulation of neuroinflammation, and more particularly, to the treatment or prevention of tauopathies or tauopathies in a subject Compositions and methods...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/14
CPCA61K31/136A61K31/47A61K41/0004A61K31/137A61K38/21A61K38/13A61K31/167A61K31/436A61K31/46A61K31/58A61K31/44A61K31/56A61P17/02A61P25/00A61P25/28A61P29/00A61P43/00A61K2300/00A61K9/08A61K9/14A61K9/16
Inventor 理查德·L·华森安东尼·B·伍德格雷戈里·J·阿咸宾
Owner REVALESIO CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com